Clinical trial

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating…

NCT00002913 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00002913
Title Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Official title PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Intervention type Biological, Drug
Interventions paclitaxel, cisplatin, topotecan hydrochloride, filgrastim
Enrollment 30
Start date Dec 1, 1996
Primary completion Jul 1, 2007
First posted Jan 27, 2003
Last update posted Jan 24, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies